Bausch Health Companies Inc. (NYSE:BHC) Receives $7.42 Average Target Price from Analysts

Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) has been given an average recommendation of "Reduce" by the seven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $7.42.

Several equities research analysts recently commented on BHC shares. Royal Bank of Canada cut their price target on Bausch Health Companies from $11.00 to $10.00 and set a "sector perform" rating for the company in a report on Thursday, January 30th. Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a research note on Thursday, February 6th.

Hedge Funds Weigh In On Bausch Health Companies

A number of hedge funds have recently modified their holdings of BHC. Tobam boosted its stake in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company's stock worth $121,000 after buying an additional 1,422 shares during the period. Toronto Dominion Bank boosted its position in shares of Bausch Health Companies by 1.0% during the 4th quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock worth $1,350,000 after purchasing an additional 1,712 shares during the period. Wells Fargo & Company MN increased its holdings in Bausch Health Companies by 7.9% in the 4th quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after purchasing an additional 1,896 shares during the last quarter. American Century Companies Inc. raised its position in Bausch Health Companies by 10.6% in the fourth quarter. American Century Companies Inc. now owns 27,236 shares of the company's stock valued at $220,000 after purchasing an additional 2,600 shares during the period. Finally, Blair William & Co. IL lifted its stake in Bausch Health Companies by 3.2% during the fourth quarter. Blair William & Co. IL now owns 84,707 shares of the company's stock worth $683,000 after purchasing an additional 2,622 shares in the last quarter. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Bausch Health Companies Stock Performance

Shares of BHC traded down $0.34 during trading hours on Tuesday, hitting $5.34. 3,167,842 shares of the stock were exchanged, compared to its average volume of 2,732,458. The stock's 50-day moving average price is $6.91 and its two-hundred day moving average price is $7.69. Bausch Health Companies has a 12-month low of $3.96 and a 12-month high of $10.46. The company has a market cap of $1.96 billion, a price-to-earnings ratio of -44.45, a price-to-earnings-growth ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last released its earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). The business had revenue of $2.56 billion for the quarter, compared to analysts' expectations of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. On average, research analysts expect that Bausch Health Companies will post 4.41 earnings per share for the current year.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.